-
Something wrong with this record ?
hsBAFF-upregulated intracellular free Ca2+ homeostasis regulates ERK1/2 activity and cell proliferation in B cells in vitro
J. Q. Liang, W. Zhang, L. Wen, W. Gao, S. Q. Zhang, L. Chen
Language English Country Czech Republic
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- B-Lymphocytes enzymology MeSH
- Butadienes pharmacology MeSH
- Time Factors MeSH
- Chelating Agents pharmacology MeSH
- Egtazic Acid analogs & derivatives pharmacology MeSH
- B-Cell Activating Factor metabolism MeSH
- Financing, Organized MeSH
- Phosphorylation MeSH
- Homeostasis MeSH
- Enzyme Inhibitors pharmacology MeSH
- Protein Kinase Inhibitors pharmacology MeSH
- Cells, Cultured MeSH
- Humans MeSH
- Mitogen-Activated Protein Kinase 1 metabolism MeSH
- Mitogen-Activated Protein Kinase 3 metabolism MeSH
- Mice, Inbred ICR MeSH
- Mice MeSH
- Nitriles pharmacology MeSH
- Cell Proliferation MeSH
- Sarcoplasmic Reticulum Calcium-Transporting ATPases antagonists & inhibitors metabolism MeSH
- Thapsigargin pharmacology MeSH
- Calcium metabolism MeSH
- Cell Survival MeSH
- Dose-Response Relationship, Drug MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
We studied hsBAFF activity in in vitro mouse splenic B cells. hsBAFF effects on intracellular free Ca2+ concentration ([Ca2+]i) were assayed, using a laser scanning confocal microscope with fluorescent probe, Fluo-3/AM. We showed that treatment of B cells with 0.5-5 µg/ml hsBAFF resulted in significantly higher [Ca2+]i levels in a dose-dependent fashion at 12 and 24 h, respectively (p<0.05 or p<0.01 vs. control). Furthermore, we noticed that 2.5 µg/ml hsBAFF-treated cells were significantly resistant to decrease of cellular viability induced by thapsigargin (Tg), an endoplasmic reticulum (ER) Ca2+-ATPase inhibitor (p<0.05 hsBAFF plus Tg group vs. Tg group). Thus hsBAFF may promote B cell survival by direct upregulation of [Ca2+]i physiological homeostasis contributing to prevention of [Ca2+]i dysfunction. Using immunocytochemistry and Western blot analysis, we found that the activation of ERK1/2 due to hsBAFF was triggered by a [Ca2+]i-dependent pathway, leading to elevation of B cell proliferation. This is supported by the findings that intracellular Ca2+ chelator BAPTA/AM attenuated phosphorylated ERK1/2 expression and cell proliferation in hsBAFF-stimulated B cells. hsBAFF-stimulated B cell proliferation was obviously reduced by mitogen extracellular kinase 1/2 (MEK1/2, upstream of ERK1/2) inhibitor U0126. Taken together, the main finding of this study is that hsBAFF elicits higher but homeostatic [Ca2+]i levels, which regulates ERK1/2 activity and cell proliferation in in vitro B cells
References provided by Crossref.org
Lit.: 23
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07530880
- 003
- CZ-PrNML
- 005
- 20111210151911.0
- 008
- 091013s2009 xr e eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.931522 $2 doi
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Liang, J. Q.
- 245 10
- $a hsBAFF-upregulated intracellular free Ca2+ homeostasis regulates ERK1/2 activity and cell proliferation in B cells in vitro / $c J. Q. Liang, W. Zhang, L. Wen, W. Gao, S. Q. Zhang, L. Chen
- 314 __
- $a College of Life Sciences, Nanjing Normal University, Jiangsu Province Key Laboratory for Molecular and Medical Biotechnology, Nanjing
- 504 __
- $a Lit.: 23
- 520 9_
- $a We studied hsBAFF activity in in vitro mouse splenic B cells. hsBAFF effects on intracellular free Ca2+ concentration ([Ca2+]i) were assayed, using a laser scanning confocal microscope with fluorescent probe, Fluo-3/AM. We showed that treatment of B cells with 0.5-5 µg/ml hsBAFF resulted in significantly higher [Ca2+]i levels in a dose-dependent fashion at 12 and 24 h, respectively (p<0.05 or p<0.01 vs. control). Furthermore, we noticed that 2.5 µg/ml hsBAFF-treated cells were significantly resistant to decrease of cellular viability induced by thapsigargin (Tg), an endoplasmic reticulum (ER) Ca2+-ATPase inhibitor (p<0.05 hsBAFF plus Tg group vs. Tg group). Thus hsBAFF may promote B cell survival by direct upregulation of [Ca2+]i physiological homeostasis contributing to prevention of [Ca2+]i dysfunction. Using immunocytochemistry and Western blot analysis, we found that the activation of ERK1/2 due to hsBAFF was triggered by a [Ca2+]i-dependent pathway, leading to elevation of B cell proliferation. This is supported by the findings that intracellular Ca2+ chelator BAPTA/AM attenuated phosphorylated ERK1/2 expression and cell proliferation in hsBAFF-stimulated B cells. hsBAFF-stimulated B cell proliferation was obviously reduced by mitogen extracellular kinase 1/2 (MEK1/2, upstream of ERK1/2) inhibitor U0126. Taken together, the main finding of this study is that hsBAFF elicits higher but homeostatic [Ca2+]i levels, which regulates ERK1/2 activity and cell proliferation in in vitro B cells
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a faktor aktivující B-buňky $x metabolismus $7 D053264
- 650 _2
- $a B-lymfocyty $x enzymologie $7 D001402
- 650 _2
- $a butadieny $x farmakologie $7 D002070
- 650 _2
- $a vápník $x metabolismus $7 D002118
- 650 _2
- $a proliferace buněk $7 D049109
- 650 _2
- $a viabilita buněk $7 D002470
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a chelátory $x farmakologie $7 D002614
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a EGTA $x analogy a deriváty $x farmakologie $7 D004533
- 650 _2
- $a inhibitory enzymů $x farmakologie $7 D004791
- 650 _2
- $a homeostáza $7 D006706
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední ICR $7 D008813
- 650 _2
- $a mitogenem aktivovaná proteinkinasa 1 $x metabolismus $7 D019950
- 650 _2
- $a mitogenem aktivovaná proteinkinasa 3 $x metabolismus $7 D048052
- 650 _2
- $a nitrily $x farmakologie $7 D009570
- 650 _2
- $a fosforylace $7 D010766
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $7 D047428
- 650 _2
- $a sarkoplazmatická Ca2+-ATPáza $x antagonisté a inhibitory $x metabolismus $7 D053498
- 650 _2
- $a thapsigargin $x farmakologie $7 D019284
- 650 _2
- $a časové faktory $7 D013997
- 700 1_
- $a Zhang, W.
- 700 1_
- $a Wen, L.
- 700 1_
- $a Gao, W.
- 700 1_
- $a Zhang, S. Q.
- 700 1_
- $a Chen, L.
- 773 0_
- $w MED00003824 $t Physiological research $g Roč. 58, č. 3 (2009), s. 411-418 $x 0862-8408
- 856 41
- $u http://www.biomed.cas.cz/physiolres/pdf/58/58_411.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 9
- 990 __
- $a 20091009100046 $b ABA008
- 991 __
- $a 20091022102928 $b ABA008
- 999 __
- $a ok $b bmc $g 689733 $s 551613
- BAS __
- $a 3
- BMC __
- $a 2009 $b 58 $c 3 $d 411-418 $i 0862-8408 $m Physiological research $x MED00003824
- LZP __
- $a 2009-32/mkme